Agonist binding to the muscarinic receptor in rat cerebral cortex membranes was studied by using the neurotransmitter itself, [3H] More recent studies indicated that binding properties of muscarinic agonists can be modulated in vitro by transition metal ions (8), GTP and its analogs (6-10, 13, 14), and the islet-activating protein, pertussis toxin (12). The mode of these modulations can be studied by the use of 3H-labeled antagonist/agonist competition experiments. However, in the complex system of 3H-labeled antagonist, agonist, receptor, and modulator, the only directly measured probe is the labeled antagonist. Thus, studies on the mechanism of muscarinic receptor modulation are highly complicated. To simplify the system, direct binding studies with labeled muscarinic agonists are required. Several groups have already demonstrated binding of 3H-labeled agonists to the high-affinity fraction of muscarinic receptors. The agonists employed were cis-[3H]methyldioxolane (13, 15) and [3H]methyloxotremorine (2, 14). The presence of low-affinity binding sites could not be demonstrated in these studies due to high nonspecific binding. Binding of [3H]AcCho to the muscarinic receptor in mouse brain has also been demonstrated (16), but the low specific radioactivity and the technique used in these studies (equilibrium dialysis) did not allow precise characterization of these interactions. However, it is highly important to establish the interaction between the muscarinic AcCho receptor and the neurotransmitter itself. We therefore undertook a study on the interactions of the radiolabeled AcCho with the muscarinic receptors in rat cerebral cortex membranes. In the present work we describe the direct binding of [3H]AcCho of high specific radioactivity to the muscarinic receptor, as well as changes in its binding induced by transition metal ions and by guanine nucleotides. A preliminary report of some of these findings has appeared (17).
was possible to demonstrate specific binding of [3HjAcCho that was sensitive to muscarinic but not to nicotinic ligands.
Equilibrium binding experiments with 5-240 nM [3H]AcCho indicated specific binding of the ligand to a saturable population of muscarinic receptors (361 ± 29 fmol/mg of protein; Kd = 76 + 17 nM). This value represented 25% of the available binding sites for a labeled antagonist in the same preparation and corresponds to the proportion of high-affinity agonist binding sites observed previously in competition experiments with labeled antagonists. Inclusion of transition metal ions (e.g., 2 mM Ni2+) in the assay increased the equilibrium binding of [3H]AcCho (628 ± 38 fmol/mg of protein, Kd = 86 ± 21 nM) but did not affect equilibrium binding of 3H-labeled antagonists, indicating conversion of low-into high-affinity muscarinic agonist binding sites. The increase developed slowly over 30 min of incubation at 25°C but could be reversed rapidly (-2 min) by the chelating agent EDTA or by guanine nucleotides. These data directly reveal a slow though quickly reversible interconversion of low-into high-affinity muscarinic agonist binding sites. Because of the technical difficulties inherent in measuring binding of 3H-labeled agonists to the muscarinic receptor by direct means (2) , attempts to further characterize the interaction of agonists with the muscarinic receptor have instead employed competition studies utilizing unlabeled agonists and 3H-labeled antagonists (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . The results of such experiments could be interpreted by assuming the existence of two or three populations of noninteracting binding sites for agonists. In cerebral cortex preparations most receptors (-75%) exhibit low affinity towards agonists (5, 8) .
More recent studies indicated that binding properties of muscarinic agonists can be modulated in vitro by transition metal ions (8) , GTP and its analogs (6-10, 13, 14) , and the islet-activating protein, pertussis toxin (12) . The mode of these modulations can be studied by the use of 3H-labeled antagonist/agonist competition experiments. However, in the complex system of 3H-labeled antagonist, agonist, receptor, and modulator, the only directly measured probe is the labeled antagonist. Thus, studies on the mechanism of muscarinic receptor modulation are highly complicated. To simplify the system, direct binding studies with labeled muscarinic agonists are required. Several groups have already demonstrated binding of 3H-labeled agonists to the high-affinity fraction of muscarinic receptors. The agonists employed were cis-[3H]methyldioxolane (13, 15) and [3H]methyloxotremorine (2, 14) . The presence of low-affinity binding sites could not be demonstrated in these studies due to high nonspecific binding. Binding of [3H]AcCho to the muscarinic receptor in mouse brain has also been demonstrated (16) , but the low specific radioactivity and the technique used in these studies (equilibrium dialysis) did not allow precise characterization of these interactions. However, it is highly important to establish the interaction between the muscarinic AcCho receptor and the neurotransmitter itself. We therefore undertook a study on the interactions of the radiolabeled AcCho with the muscarinic receptors in rat cerebral cortex membranes. In the present work we describe the direct binding of [3H]AcCho of high specific radioactivity to the muscarinic receptor, as well as changes in its binding induced by transition metal ions and by guanine nucleotides. A preliminary report of some of these findings has appeared (17) .
MATERIALS AND METHODS Materials. [3H]AcCho of high specific radioactivity (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) Ci/mmol, 97% purity; 1 Ci = 37 GBq) was purchased from Amersham. Its synthesis and purity determinations have recently been described in detail (18) . The radiochemical was kept at -70°C in small aliquots in ethanol/water (1:1, vol/ vol), which were dried by a gentle stream of nitrogen prior to assay. Three different batches of [3H]AcCho that were used in the course of this study yielded essentially the same results.
Tissue Preparation. Cerebral cortex homogenates were prepared from four or five male rats (C-D strain) in 50 vol of 50 mM Tris HCl buffer, pH 7.4, as described (3, 19) . The homogenate was incubated for 30 min at 25°C with gentle shaking and then centrifuged at 30,000 x g for 15 min. This procedure was repeated twice. The final pellet was resuspended in modified Krebs buffer containing 25 mM Tris-HCl (pH 7.4, 25°C). A fresh solution of diisopropyl fluorophosphate (iPr2P-F; Sigma lot 82F-0450) in water was added to the homogenate to achieve a concentration of 200 AM. The homogenate was incubated for a further 30 min at 25°C prior to binding assay. In some assays neostigmine or physostigmine was used instead of iPr2P-F. Protein concentration was determined according to the Lowry method, using bovine serum albumin as a standard.
[3H]AcCho Binding Assay. Aliquots (20 ,ul) 
3650
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
to tubes containing 20 A.l of modified Krebs buffer, 200 ,AM iPr2P-F, and the indicated concentrations of [3H]AcCho. After the indicated time of incubation with gentle shaking at 250C, 4 ml of ice-cold modified Krebs buffer was added and the contents of the tubes were filtered under high pressure through GF/C filters (Whatman, 25-mm diameter). The filters were immediately washed with an additional 2 ml of buffer; the time that elapsed between the addition of buffer to the tube and the termination of filtration was 2-2.5 sec.
Specific binding was taken as the difference between the total binding to control membranes and the measured nonspecific binding-i.e., binding to membranes after adding 20 ,tM atropine during the last 10 min of the preincubation step.
The same values for nonspecific binding were obtained when 20 AtM oxotremorine was substituted for atropine. Under the experimental protocol described, there was no detectable specific binding to GF/C filters alone, or to membranes heated to 70'C for 10 min.
All determinations were carried out in quadruplicate, each one varying by <15%. Centrifugation assays were carried out by using a similar protocol, but bound and free ligand were separated by centrifugation in an Eppendorf microcentrifuge (10,000 x g, 2 min), followed by superficial washing of the membrane pellet three times with 1 ml of ice-cold buffer and determination of radioactivity in the pellets.
[3H]4NMPB Binding. Aliquots (20 ul two components, one that could be inhibited by 10 ,M atropine or 10 ,uM oxotremorine (specific binding), and one that could not be inhibited by these muscarinic drugs (nonspecific binding (Fig. 1B) . Thus, apparent inhibition constants (nM) of 0.20, 0.25, 0.55, 0.60, and 3.0 were determined for the antagonists quinuclidinyl benzilate, Nmethylscopolamine, 4 NMPB, scopolamine, and atropine, respectively. The apparent inhibition constants (nM) for agonists were 17, 320, 550, and 1100 for oxotremorine, carbamoylcholine, arecoline, and pilocarpine, respectively. These apparent inhibition constants (K1) were (Fig. 4) Co2. or Mn2 , which increased [3H]AcCho binding to the same extent but at higher concentrations (half-maximal increase at 0.4 and 0.7 mM, respectively).
Binding isotherms describing the specific [3HjAcCho binding to the muscarinic receptor in rat cerebral cortex membranes in the absence and presence of 2 mM Ni2+ are shown in Fig. 2B . A definite increase in the specific binding of [3H] AcCho is observed at all ligand concentrations studied. Replotting the data according to Scatchard yields two parallel lines (Fig. 3) (Fig. 4) (Fig. 4) 
DISCUSSION
The present work describes the atropine-sensitive binding of [3H]AcCho to receptors in rat cerebral cortex membranes. Binding of [3H]AcCho to these receptors is inhibited by muscarinic ligands with the expected rank-order potency, but not by nicotinic ligands (Fig. 1B) , and thus represents highaffinity binding to putative muscarinic receptors in the membranes. The validity of the assay conditions has been verified by comparing the binding of [3H]AcCho in the centrifugation and filtration methods, by comparing the binding data under the standard assay conditions with a 1:5-diluted preparation, and by examining the effect of long-term incubations (2 hr). All these tests yielded results similar to those obtained under the standard conditions, thus eliminating substantial interference of parameters such as dissociation of bound ligand, ligand degradation, or the presence of endogenous AcCho.
The (2) and cis-3-methyldioxolane (13, 15) , indicated the existence of "super-high affinity" sites. Under our assay conditions there was also a hint for the existence of such sites for AcCho. However, further studies at the subnanomolar AcCho range are required to characterize this phenomenon.
Low-affinity agonist binding sites, evaluated from competition experiments with 3H-labeled antagonists, represent -75% of the available antagonist binding sites in cerebral cortex membranes. In spite of their high proportion, attempts to demonstrate them directly by using [3H]AcCho (in our experiments) and other labeled agonists (2, 13, 15) have failed. Binding of [3H]AcCho to the putative low-affinity sites would occur at the micromolar concentration range (2) (3) (4) (5) . Under the assay conditions employed, nonspecific binding of [3H]AcCho at such concentrations would be >10 times higher than its specific binding to muscarinic receptors, thus precluding reliable measurements and consequently preventing determination of the exact stoichiometry of [3H]AcCho/3H-labeled antagonist binding sites. We may safely conclude, however, that at the nanomolar concentration range and under the standard assay conditions employed, one AcCho molecule binds with high affinity to the muscarinic receptor for every four antagonist molecules. This stoichiometry can be increased to one agonist molecule bound for two antagonist molecules in the presence of transition metal ions. Together with the lack of change in [3H]4NMPB binding in the presence of 2 mM Ni2+, these findings provide direct evidence that interconversion between low-and highaffinity states of the muscarinic receptor towards agonists (8) involves an actual increase in the number of high-affinity sites, with no change in the total number of antagonist sites. This demonstration that low-affinity agonist sites can be converted to high-affinity (or back to low affinity by either guanine nucleotides or EDTA) suggests that the same muscarinic receptors can exist either in low-or high-affinity states. As for the remaining 50% of the receptors, which apparently remained in the low-affinity form, there are two possible explanations: (i) They could represent a separate class of receptors that are incapable of interconversion. (ii) Alternatively, these receptors may undergo interconversion, but under conditions different from those employed here. The latter possibility would imply the existence of an equilibrium between low-and high-affinity states of the muscarinic receptors, which can be altered under various experimental conditions.
Mechanisms leading to such reversible transitions could involve conformational changes induced directly by the modulators or indirect modifications through the activation of specific enzymes (21) . Possible targets for these changes are the muscarinic binding sites, a guanyl-nucleotide binding protein (12, 21, 22) , or the coupling between these two. Involvement of a guanyl-nucleotide binding protein in the interconversion process is suggested by the fast reversal of the Ni2W effect by GTP. These findings are in accord with the proposal that the binding of GTP to its binding protein induces the dissociation of the latter from the muscarinic receptor, transferring the receptor to a low-affinity state towards agonists (12, 21, 22) .
